328 related articles for article (PubMed ID: 31836930)
1. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
J Gastroenterol; 2020 Mar; 55(3):291-306. PubMed ID: 31836930
[TBL] [Abstract][Full Text] [Related]
2. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
PLoS One; 2019; 14(2):e0212989. PubMed ID: 30807613
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.
Sands BE; Van Assche G; Tudor D; Akhundova-Unadkat G; Curtis RI; Tan T
Inflamm Bowel Dis; 2019 Jul; 25(8):1375-1382. PubMed ID: 30615117
[TBL] [Abstract][Full Text] [Related]
9. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
10. Long-term Efficacy of Vedolizumab for Crohn's Disease.
Vermeire S; Loftus EV; Colombel JF; Feagan BG; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
J Crohns Colitis; 2017 Apr; 11(4):412-424. PubMed ID: 27683798
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
[TBL] [Abstract][Full Text] [Related]
16. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
20. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
